Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas
Phase of Trial: Phase II/III
Latest Information Update: 06 Aug 2019
Price : $35 *
At a glance
- Drugs Insulin aspart (Primary) ; Insulin lispro (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 01 Aug 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
- 26 Apr 2019 Planned number of patients changed from 30 to 45.
- 26 Apr 2019 Status changed from not yet recruiting to recruiting.